Blocking M2-activating cytokines (IL-13, IL-4, IL-10) also enhances efficacy, including immune checkpoint inhibitors (84), as high IL-10 in TAMs is linked to NSCLC staging (141). Here, IL10 is linked to non-small cell lung carcinoma.